Author name: Leonardo Arias

Monogram Technologies’ surgical robot for total knee replacements is expected to give Zimmer Biomet’s customers more options and drive robotic knee adoption in the U.S.

The transaction, expected to close in the third or fourth quarter, will take Walgreens private after nearly 100 years as a public company.

The BD business will be spun off and merged with a Waters subsidiary. Waters shares were down about 11% in early trading Monday on the news.

The drug came to AstraZeneca through its acquisition of CinCor Pharma in 2023, with the hopes of beefing up its cardiovascular and kidney disease pipelines.

Despite the FDA commissioner’s promises of partnership and collaboration, personnel changes and continued federal cuts create uncertainty for an industry already struggling with nearly half a decade of investment scarcity.

Takeda’s oveporexton improved wakefulness, attention and other key narcolepsy endpoints “with a high degree of statistical significance,” according to Jefferies analysts.

President Donald Trump unveiled the new duty rates, set to begin Aug. 1, in separate letters shared on social media Saturday morning. 

The development saga for the depression molecule has been rocky for years, unable to ease symptoms in multiple late-stage trials.

Through its recently unveiled Priority Voucher program, the FDA seeks to accelerate the review process for companies that promise to keep prices down.

The FDA cited manufacturing issues but did not flag problems with Ultragenyx’s data package for UX111, with the biotech noting that the regulator found its neurodevelopmental findings for the gene therapy to be “robust.”